Videos

Five-year progression-free survival in the CLL14 trial is approximately 63% in the targeted treatment arm, according to new data.

Medication adherence is critical to control the symptoms of congestive heart failure.

Blinded independent central review analysis also adds confidence to the findings.

The ability to measure GFR would be a significant advancement for clinicians in the United States.

Beth Koselke, PharmD, BCOP, discusses the impact of pharmacist intervention in clinical trial enrollment, specifically in the MYLUNG Consortium.

Nicholas Robert, MD, chief medical officer at Ontada, discusses disparities in biomarker testing and how they are being addresses at ASCO 2022 Annual Meeting.

New results from the ATHENA-MONO trial investigating the use of rucaparib in patients with ovarian cancer show promise.

The trial achieved a complete remission rate of 39.4%, which researcher Michael Dickinson, MBBS, DMedSci, called "remarkable."

Circulating tumor DNA tests could someday replace CT scans for cancer management, according to Bruce Feinberg, DO.

Bruce Feinberg, DO, vice president and chief medical officer at Cardinal Health Specialty Solutions, discussed how a cancer diagnosis and treatment can impact patients’ mental health.

Pharmacy Times spoke with Amila Patel, PharmD, chief clinical officer at Navigating Cancer, to learn about digital health solutions in oncology and what she sees for the future of these solutions.

Kelly McAuliff, PharmD, BCOP, CSP, spoke about research into the impacts of the COVID-19 pandemic on oral oncolytic adherence, particularly for patients with ovarian cancer, prostate cancer, or chronic myelogenous leukemia.

Both patients and providers should recognize the benefits of early referrals to palliative care.

Ahmed Kotb, MD, vice president of US medical affairs, oncology, at AbbVie, discussed new findings from the REFINE trial and what they could mean for patients with myelofibrosis.

With several recent approvals, new CAR T therapies are having significant impacts in multiple myeloma treatment.

Ken Blount, PhD, chief scientific officer at Rebiotix, discusses the investigative treatment RBX2660 and its unique approach to treating Clostridioides difficile infection.

Ogi Kavazovic, co-founder and CEO of House Rx, discusses the company's technology platform and pharmacy service and how it can better enable community oncology pharmacy practices to offer medically integrated dispensing.

Tesh Khullar, co-founder and president of House Rx, discusses how social determinants of health can impact time to treatment initiation.

A panel of experts discuss allergic rhinitis and important counseling points and tactics. They review the current standard of care and identify specific treatment considerations for children, women, elderly, and others.

We're rowing in the same direction as pharmacists, so that what is of interest to a payer, PBMs and pharmacies, according to PQA.

We spoke with Kelly McAuliff, PharmD, BCOP, CSP, to learn about data being presented at the ASCO 2022 Annual Meeting.

Drs Haumschild, Howe, and Gilreath contribute their final perspectives for maximizing care management between providers and patients with myeloproliferative neoplasms.

Pharmacy specialists discuss quality initiatives in MPN management by sharing advice on assessing symptoms and patient adherence.

Just making sure that everybody has a seat at the table is the most important thing at PQA.

PQA wants to expand the types of services covered and report on the results of the current examples that are profiled in the SDOH guide.

The challenges in pharmacy are really a lack of standardization.

Pharmacists are ideally positioned to screen patients for estimation aids and then refer them to services.

Pharmacists are an important touch point for PQA, and they're starting small and thinking big.

Linaclotide (Linzess) is indicated in adults for treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.

PQA is also committed to national goals related to HIV and reducing HIV ending the epidemic.